GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TherapeuticsMD Inc (NAS:TXMD) » Definitions » Price-to-Owner-Earnings

TherapeuticsMD (TherapeuticsMD) Price-to-Owner-Earnings : (As of Apr. 30, 2024)


View and export this data going back to 2007. Start your Free Trial

What is TherapeuticsMD Price-to-Owner-Earnings?

As of today (2024-04-30), TherapeuticsMD's share price is $1.89. TherapeuticsMD does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for TherapeuticsMD's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of TherapeuticsMD was 1.91. The lowest was 0.26. And the median was 1.16.


TXMD's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 28.39
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-30), TherapeuticsMD's share price is $1.89. TherapeuticsMD's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.99. Therefore, TherapeuticsMD's PE Ratio for today is At Loss.

As of today (2024-04-30), TherapeuticsMD's share price is $1.89. TherapeuticsMD's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.75. Therefore, TherapeuticsMD's PE Ratio without NRI for today is At Loss.

During the past 13 years, TherapeuticsMD's highest PE Ratio without NRI was 61.11. The lowest was 0.00. And the median was 1.25.


TherapeuticsMD Price-to-Owner-Earnings Historical Data

The historical data trend for TherapeuticsMD's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TherapeuticsMD Price-to-Owner-Earnings Chart

TherapeuticsMD Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.66 -

TherapeuticsMD Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.66 0.28 1.85 1.74 -

Competitive Comparison of TherapeuticsMD's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, TherapeuticsMD's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TherapeuticsMD's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TherapeuticsMD's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where TherapeuticsMD's Price-to-Owner-Earnings falls into.



TherapeuticsMD Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

TherapeuticsMD's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.89/-3.88
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TherapeuticsMD  (NAS:TXMD) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


TherapeuticsMD Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of TherapeuticsMD's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


TherapeuticsMD (TherapeuticsMD) Business Description

Traded in Other Exchanges
Address
951 Yamato Road, Suite 220, Boca Raton, FL, USA, 33431
TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products. TherapeuticsMD's drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and discomfort. The company relies on third parties for the production of clinical and commercial quantities of its drug candidates.
Executives
Marlan D Walker officer: General Counsel 951 YAMATO ROAD, SUITE 220, BOCA RATON FL 33431
Joseph Ziegler officer: Principal Financial Officer 1051 HILLSBORO MILE, PH2, HILLSBORO BEACH FL 33062
Michael C Donegan officer: CAO and VP of Finance 6800 BROKEN SOUND PARKWAY NW, THIRD FLOOR, BOCA RATON FL 33487-3507
Rubric Capital Management Lp 10 percent owner 155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
Brian Bernick director 951 BROKEN SOUND PARKWAY NW, SUITE 320, BOCA RATON FL 33487
Gail K Naughton director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Mark A Glickman officer: Chief Business Officer C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Justin Hunter Roberts director C/O RUBRIC CAPTIAL MANAGEMENT LP, 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105
Karen Ling director C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Paul Bisaro director
Angus C. Russell director C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Jules A. Musing director 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
David Efraim Rosen 10 percent owner 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Collins Cooper C. director 33219 FOREST WEST DRIVE, MAGNOLIA TX 77354

TherapeuticsMD (TherapeuticsMD) Headlines

From GuruFocus

TherapeuticsMD Announces Additional $7 Million Private Placement

By Business Wire Business Wire 10-31-2022